Opinion|Videos|May 29, 2024
Overcoming Barriers to Better Patient Outcomes in PAH
Author(s)Ronald Oudiz, MD, FACP, FACC, FCCP
Ronald Oudiz, MD, FACP, FACC, FCCP, discusses the challenges and limitations associated with the adoption of new treatments and the impact of emerging therapies on patient outcomes, quality of life, and disease management in the long term.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What are the potential challenges or limitations associated with the adoption of new treatments, such as cost, access, or safety concerns?
- How might the evolving treatment landscape for PAH impact patient outcomes, quality of life, and disease management in the long term?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Vutrisiran Improves Survival, Cardiovascular Outcomes Across Age Groups in ATTR-CM
2
Contributor: The Majority (57.5%) of Commercially Insured Patients Had 1 or More Chronic Conditions in 2024
3
Prior Authorization Ranked Top Barrier to Health Care Access After Cost
4
Most Patients With MCL in Study of Pirtobrutinib Show Stable or Improved Physical Symptoms, QOL
5
